Phillip Frost
Net Worth
Last updated:
What is Phillip Frost net worth?
The estimated net worth of Dr. Phillip Frost is at least $300,521,044 as of 13 Dec 2024. He owns shares worth $286,924,244 as insider and has received compensation worth at least $13,596,800 in OPKO Health, Inc..
What is the salary of Phillip Frost?
Dr. Phillip Frost salary is $971,200 per year as Chairman & Chief Executive Officer in OPKO Health, Inc..
How old is Phillip Frost?
Dr. Phillip Frost is 89 years old, born in 1936.
What stocks does Phillip Frost currently own?
As insider, Dr. Phillip Frost owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
OPKO Health, Inc. (OPK) | Chairman & Chief Executive Officer | 212,536,477 | $1.35 | $286,924,244 |
What does OPKO Health, Inc. do?
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.